SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced it will participate in four healthcare equity conferences in September:
- H.C. Wainwright & Co. 22nd Annual Global Investment Conference: presentation on
Monday, September 14, 2020 from 3:30 to 3:50 p.m. EST.
- 2020 Cantor Global Virtual Healthcare Conference: virtual fireside chat on
Wednesday, September 16, 2020 from 4:00 p.m. to 4:30 p.m. EST.
- Morgan Stanley 18th Annual Global Healthcare Conference: virtual fireside chat on
Friday, September 18, 2020 from 11:00 a.m. to 11:30 a.m. EST.
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: virtual fireside chat on
Tuesday, September 22, 2020 from 10:50 a.m. to 11:30 a.m. EST.
About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. For more information, please visit www.evofem.com.
Phexxi™ is a trademark of Evofem Biosciences, Inc.
Evofem Biosciences, Inc.
M: (917) 673-5775
M: (413) 478-2003
SOURCE Evofem Biosciences, Inc.